Ftorafur®

Ftorafur® is the leading agent of the anticancer group, a widely used chemotherapeutic drug for the treatment of malignant tumors, particularly gastric, colorectal and breast cancer.  

Ftorafur® is synthesized in 1964 in the Institute of Organic Synthesis of the Latvian Academy of Sciences, and its discovery could be considered as an essential step in the development of chemotherapy. Experimental and clinical investigations of Ftorafur® took place in the USSR, Japan, USA and some European countries; since 1969 active co-operation took place with Japanese companies Taiho Pharmaceutical and Iskra.

Ftorafur® is registered in Latvia, Poland, Romania, Hungary, China etc. It takes a significant place in the total sales volume of «Grindeks» as leading a export product. Ftorafur® active pharmaceutical ingredient is exported to Japan since 1972, though the final dosage form - 400 mg capsules - are sold in Baltic and CIS countries, Japan, as well as in the markets of several European countries.

«Grindeks»is working on the further development of Ftorafur® in accordance with the latest developments in cancer treatments and the latest trends in global pharmaceuticals.